Laboratory & Diagnostic Services
Clinical and anatomic pathology laboratories, genetic testing providers, and toxicology labs serving healthcare clients.
- 4
- Verticals
Overview
Laboratory & Diagnostic Services covers clinical and anatomic pathology laboratories, genetic-testing providers, and toxicology labs. The reference-lab market is consolidated around Labcorp and Quest Diagnostics, alongside a growing field of specialty and genomic-testing companies.
The segment saw an extraordinary COVID-testing surge in 2020–22 that inflated revenue before normalizing, while the durable growth driver is the expansion of molecular, genetic, and precision-diagnostics testing. It is consolidating, with the majors acquiring hospital outreach labs and specialty testing capabilities.
Market snapshot
- Market size
- ~$76B
- Growth
- ~10.1%CAGR (2017–22, nominal)
- Companies
- ~4,829 firms
75.3% of firms have fewer than 20 employees: 3,638 micro-businesses, below most mandates.
- 20–99
- 63453%
- 100–499
- 30926%
- 500+
- 24821%
~4,800 medical-lab and blood/organ-bank firms; the ~10%/yr growth and ~$76B are inflated by the 2022 COVID-testing surge and will normalize lower. It is a scaling, consolidating services layer (Labcorp and Quest at the top) with a long fragmented tail of specialty and reference labs — a deep strategic-buyer pool.
NAICS 621511, 621991. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.
Business model & economics
Revenue model
Per-test reimbursement across clinical and specialty testing
Key economics
- Revenue per firm
- $15,732,062
- Revenue per employee
- $224,750
- Employees per firm
- 67.5
- Recurring revenue
- Moderate–High
- EBITDA margin
- 15–25%
- Capex intensity
- High
recurring testing volume
Characteristics
- Balanced cost base — payroll is 29% of revenue, leaving room to scale margin without cutting staff
- Deep strategic-buyer pool — 248 firms exceed 500 employees, so a scaled asset has trade buyers
- Reference-lab market consolidated around Labcorp and Quest.
- COVID-testing surge inflated 2020–22, then normalized.
- Molecular and genetic testing the durable growth driver.
NAICS 621511, 621991. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.
M&A deal context
Who’s acquiring
- Reference-lab majors
- Genomic & specialty-testing acquirers
- PE-backed lab consolidators
What’s driving deals
- Acquisition of hospital outreach and specialty labs.
- Molecular and precision-diagnostics growth.
- Consolidation around scaled reference labs.
Verticals in this segment
Find Laboratory & Diagnostic Services acquisition targets
Search Acquisera’s index for companies classified under Laboratory & Diagnostic Services (4.9.5) and build a targeted deal pipeline.
Search companies